{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:51:45Z","timestamp":1791881505807,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaad.2025.12.039","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:32:23Z","timestamp":1765989143000},"page":"1184-1192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cancer progression, recurrence, and infection outcomes in psoriasis patients with active or recent malignancy treated with biologic therapy: A cohort study showing comparable safety to conventional agents"],"prefix":"10.1016","volume":"94","author":[{"given":"Danielle","family":"Bar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lital","family":"Brilant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merav","family":"Lidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviv","family":"Barzilai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaad.2025.12.039_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12016-012-8301-7","article-title":"Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring","volume":"44","author":"Sivamani","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2025.12.039_bib2","article-title":"Adverse effects of biologics: a network meta-analysis and cochrane overview","volume":"2011","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.jaad.2025.12.039_bib3","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/jdv.16073","article-title":"Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies","volume":"34","author":"Loft","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.039_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/1346-8138.14096","article-title":"Safety of biologics in psoriasis","volume":"45","author":"Kamata","year":"2018","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.039_bib5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.04.139","article-title":"The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: a systematic analysis from the Global Burden of Disease Study 2017","volume":"84","author":"Mehrmal","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.039_bib6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network","volume":"152","author":"Chiesa Fuxench","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2025.12.039_bib7","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamadermatol.2019.3056","article-title":"Association of psoriasis with the risk of developing or dying of cancer: a systematic review and meta-analysis","volume":"155","author":"Trafford","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.039_bib8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40257-017-0337-2","article-title":"Malignancy risk and recurrence with psoriasis and its treatments: a concise update","volume":"19","author":"Geller","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.039_bib9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10091","key":"10.1016\/j.jaad.2025.12.039_bib10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.039_bib11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"10201","key":"10.1016\/j.jaad.2025.12.039_bib12","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"10148","key":"10.1016\/j.jaad.2025.12.039_bib13","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2025.12.039_bib14","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/jdv.14114","article-title":"Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis","volume":"31","author":"Gisondi","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.jaad.2025.12.039_bib15","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/jdv.14470","article-title":"Methods report: European S3-guideline on the systemic treatment of psoriasis vulgaris - update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC","volume":"31","author":"Dressler","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.039_bib16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000083509","article-title":"The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis","volume":"210","author":"Schmitt","year":"2005","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.jaad.2025.12.039_bib17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"6","key":"10.1016\/j.jaad.2025.12.039_bib18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"408","key":"10.1016\/j.jaad.2025.12.039_bib19","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The robust inference for the Cox proportional hazards model","volume":"84","author":"Lin","year":"1989","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.039_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: a systematic review","volume":"178","author":"Peleva","year":"2018","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.039_bib21","doi-asserted-by":"crossref","first-page":"20690","DOI":"10.1038\/s41598-022-23518-w","article-title":"Risk of malignancy in patients with psoriasis according to treatment modalities in Korea: a nationwide cohort study","volume":"12","author":"Hong","year":"2022","journal-title":"Sci Rep"},{"issue":"19","key":"10.1016\/j.jaad.2025.12.039_bib22","doi-asserted-by":"crossref","first-page":"17093","DOI":"10.1007\/s00432-023-05387-6","article-title":"Cancer risks in patients with psoriasis administered biologics therapy: a nationwide population-based study","volume":"149","author":"Jung","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.jaad.2025.12.039_bib23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/jdv.19520","article-title":"Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-insights from an international population-based study","volume":"38","author":"Kridin","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2025.12.039_bib24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2023.03.035","article-title":"Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: pooled results from the VOYAGE 1 and VOYAGE 2 trials","volume":"89","author":"Blauvelt","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.12.039_bib25","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamadermatol.2025.2056","article-title":"Ixekizumab and malignant neoplasms: a pooled analysis of data from 25 randomized clinical trials","volume":"161","author":"Merola","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.12.039_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2025.12.039_bib27","series-title":"Abstract 1777. 24th European Academy of Dermatology and Venereology (EADV) Congress","article-title":"Experience in patients with a history of malignancy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) study","author":"Langley","year":"2015"},{"issue":"5","key":"10.1016\/j.jaad.2025.12.039_bib28","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1080\/09546634.2021.1970706","article-title":"Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?","volume":"33","author":"Mastorino","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.jaad.2025.12.039_bib29","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1111\/jdv.19603","article-title":"Biologics in psoriatic patients with malignancies: where are we now? An Italian multicentric study","volume":"38","author":"Magnano","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jaad.2025.12.039_bib30","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1007\/s13555-022-00797-9","article-title":"Secukinumab in patients with psoriasis and a personal history of malignancy: a multicenter real-life observational study","volume":"12","author":"Pellegrini","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"10.1016\/j.jaad.2025.12.039_bib31","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1111\/jdv.15775","article-title":"A real-life experience of psoriatic patients with history of cancer treated with biological drugs","volume":"33","author":"Odorici","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2025.12.039_bib32","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1080\/09546634.2021.1886231","article-title":"Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population","volume":"33","author":"Valenti","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.jaad.2025.12.039_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14889","article-title":"IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: a case series with systematic literature review","volume":"34","author":"Bellinato","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2025.12.039_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113928","article-title":"New insights into the IL-12 and IL-23: from a molecular basis to clinical application in immune-mediated inflammation and cancers","volume":"175","author":"Chyuan","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jaad.2025.12.039_bib35","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190297","article-title":"The role of interleukin-17 in tumor development and progression","volume":"217","author":"Zhao","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2025.12.039_bib36","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaad.2025.12.039_bib37","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.3390\/cancers13081775","article-title":"Dual role of TNF and LT\u03b1 in carcinogenesis as implicated by studies in mice","volume":"13","author":"Gubernatorova","year":"2021","journal-title":"Cancers"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225034206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225034206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T08:26:22Z","timestamp":1791879982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225034206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0190962225034206"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.12.039","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer progression, recurrence, and infection outcomes in psoriasis patients with active or recent malignancy treated with biologic therapy: A cohort study showing comparable safety to conventional agents","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.12.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}